Omvoh (mirikizumab)
Research Synopsis
- * Mirikizumab has demonstrated a 67% achievement rate in significant skin improvement at the highest dose during a phase II clinical trial for psoriasis.
- * Studies emphasize the role of IL-23 in autoimmune disorders, particularly in psoriasis and inflammatory bowel diseases such as ulcerative colitis and Crohn's disease.
- * Recent findings indicate that mirikizumab is undergoing phase II trials for ulcerative colitis, although results have been mixed with no statistically significant primary endpoint outcomes yet.
- * The IL-23 axis continues to be a critical target in inflammatory diseases, with mirikizumab and similar agents providing safer and more effective therapeutic options compared to existing treatments.
- * Ongoing research focuses on the comparative long-term effectiveness of mirikizumab against other anti-IL-23 therapies and its incorporation into treatment plans for ulcerative colitis and psoriasis.
- * The potential for mirikizumab to be used in tandem with other treatments for conditions linked to the IL-23 pathway is also being explored.
- * Mirikizumab's clinical trials stress the emphasis on patient safety, revealing comparable side effects with placebo groups in early studies.
- * The drug has been extensively reviewed in recent literature, underscoring its promising role in the future landscape of biologic treatments for chronic inflammatory conditions.
- * Continued exploration into the mechanisms of action and patient response variations is critical to fully elucidate the benefits and risks associated with mirikizumab.
Omvoh (mirikizumab)
Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis?
London, UK
2 hours ago
1 Received
- - Advances in biotechnology and disease understanding have led to targeted treatments for immune-mediated inflammatory diseases (IMIDs), allowing for better therapies and insights into disease mechanisms.
- - The review discusses various novel biologic agents that target specific immune pathways, including interleukins (IL-17, IL-12/23, IL-23), type I and II interferons, and strategies to inhibit lymphocyte recruitment and JAK signaling.
- - It also highlights new treatments directed at B-cells and regulatory T-cells, as well as innovative biotechnological developments like bispecific antibodies that may improve IMID management.
$100 - $150
Hourly Rate
Interleukin 23 in the skin: role in psoriasis pathogenesis and selective interleukin 23 blockade as treatment.
London, UK
2 hours ago
1 Received
- Plaque psoriasis is a common autoimmune skin disease marked by red, scaly patches and has seen significant advancements in treatment.
- New therapies target the IL-23/IL-17 immune pathway, making this condition much easier to manage.
- The article discusses the immune processes involved in psoriasis and reviews new IL-23 antagonists that help treat this chronic skin condition effectively.
$100 - $150
Hourly Rate
Investigational drugs in phase I and phase II clinical trials targeting interleukin 23 (IL23) for the treatment of Crohn's disease.
London, UK
2 hours ago
1 Received
- Medical therapy for Crohn's disease focuses on reducing intestinal inflammation to prevent complications, but current treatments don't work for everyone, highlighting the need for new options.
- The IL-23 cytokine pathway is important in Crohn's disease development, leading to research on targeting this pathway with specific monoclonal antibodies, such as risankizumab and brazikumab.
- Early phase clinical trials suggest that IL-23 targeting might be safer and more effective than existing treatments, with further studies in the pipeline to confirm their role in treating Crohn's disease.
$100 - $150
Hourly Rate
IL-23 inhibitors for moderate-to-severe psoriasis.
London, UK
2 hours ago
1 Received
- * Two inhibitors, guselkumab and tildrakizumab, have gained FDA approval, while risankizumab and mirikizumab are in advanced clinical trials.
- * These medications show high effectiveness and safety, with the added benefit of less frequent dosing for patients.
$100 - $150
Hourly Rate
Anti-interleukin-12 and anti-interleukin-23 agents in Crohn's disease.
London, UK
2 hours ago
1 Received
- Blockers of IL-12/23 and IL-23 are being studied as treatments for inflammatory bowel disease, with ustekinumab being the first drug to show effectiveness in conditions like Crohn's disease.
- The review discusses the rationale behind targeting the IL-12/23 pathway, along with safety and efficacy data from trials and ongoing research on selective IL-23 inhibitors.
- While ustekinumab is promising due to its quick effect and good safety profile, further research is needed to solidify its effectiveness in real-world scenarios.
$100 - $150
Hourly Rate
A SPECIAL MEETING REVIEW EDITION: Highlights in Inflammatory Bowel Disease From the 14th Congress of ECCO: A Review of Selected Presentations From the 14th Congress of the European Crohn's and Colitis Organisation (ECCO) • March 6-9, 2019 • Copenhagen, Denmark• VARSITY: A Double-Blind, Double-Dummy,
London, UK
2 hours ago
1 Received
$100 - $150
Hourly Rate
Efficacy and safety of mirikizumab (LY3074828) in the treatment of moderate-to-severe plaque psoriasis: results from a randomized phase II study.
London, UK
2 hours ago
1 Received
- In a phase II double-blind trial, researchers tested mirikizumab, an IL-23 antibody, against placebo in patients with moderate-to-severe plaque psoriasis to assess its effectiveness and safety.
- 109 adult patients were randomly assigned to receive either mirikizumab at 30 mg, 100 mg, or 300 mg, or a placebo, with the goal of achieving a 90% improvement in psoriasis severity at week 16.
- At week 16, 67% of those treated with the highest dose of mirikizumab achieved significant skin improvement compared to lower rates in the placebo group, with similar occurrences of side effects between both groups.
$100 - $150
Hourly Rate
Mini Review: New Treatments in Psoriatic Arthritis. Focus on the IL-23/17 Axis.
London, UK
2 hours ago
1 Received
- * Interleukin (IL)-17 is crucial in the progression of both conditions, with IL-23 supporting IL-17's role, making the IL-23/IL-17 signaling pathway a key target for new treatments.
- * Current and emerging therapies include monoclonal antibodies targeting IL-23 and IL-17, as well as Janus tyrosine kinase (JAK) inhibitors, which have shown effectiveness in treating psoriasis and PsA.
$100 - $150
Hourly Rate
IL12/23 or selective IL23 inhibition for the management of moderate-to-severe Crohn's disease?
London, UK
2 hours ago
1 Received
- - The IL-12 family of cytokines, particularly IL-12 and IL-23, contribute to abnormal immune responses in Crohn's disease (CD), leading to new treatment strategies.
- - Ustekinumab, a monoclonal antibody targeting the common p40 subunit of IL-12 and IL-23, has been effective for both new patients and those unresponsive to TNF antagonists.
- - Recent developments focus on IL-23 p19 antagonists, which show higher efficacy in trials for various conditions, and promising results are emerging for CD treatments like risankizumab and brazikumab entering advanced stages of testing.
$100 - $150
Hourly Rate
Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis.
London, UK
2 hours ago
1 Received
- Interleukin 23 is linked to ulcerative colitis (UC), and a phase 2 study was conducted to assess the monoclonal antibody mirikizumab's effectiveness on UC patients across 14 countries from 2016 to 2017.
- Patients with moderate to severe UC were randomly assigned to receive either mirikizumab at different doses or a placebo, with the primary goal being to achieve clinical remission by week 12.
- The study found that while some patients on mirikizumab showed clinical responses, the primary endpoint of clinical remission was not statistically significant, indicating mixed results in the effectiveness of the treatment.
$100 - $150
Hourly Rate
Anti-interleukin-23 agents for the treatment of ulcerative colitis.
London, UK
2 hours ago
1 Received
- Treatment for ulcerative colitis (UC) focuses on managing symptoms and reducing inflammation, but not all patients respond to available medications.
- The interleukin (IL)-23 axis is crucial in UC development, making it a key target for new drug creation, with several anti-IL-23 treatments like ustekinumab and mirikizumab showing promise in recent trials.
- Ongoing research aims to compare these therapies with existing ones and evaluate long-term effectiveness and safety, while also considering how to best incorporate IL-23 antagonists in treatment plans.
$100 - $150
Hourly Rate
Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review.
London, UK
2 hours ago
1 Received
- Around 125 million people globally suffer from psoriasis, leading to significant health issues, including inflammatory arthritis, heart diseases, and mental health problems.
- The most common type, plaque psoriasis, involves serious comorbidities and has seen advancements in understanding its causes and treatment options, especially biologics.
- Treatment varies based on severity, with mild cases managed by topical agents and moderate to severe cases often treated with biologics, which target specific inflammatory pathways, providing both efficacy and safety.
$100 - $150
Hourly Rate
Treatment of psoriasis: janus kinases inhibitors and biologics for the interleukin-23/Th17 axis.
London, UK
2 hours ago
1 Received
- The study investigates advancements in biologics and JAK inhibitors targeting the IL-23/Th17 axis as new treatments for psoriasis.
- It reviews data from multiple clinical trials, focusing on skin lesion clearance and major side effects of monoclonal antibodies like mirikizumab and bimekizumab.
- The paper highlights the potential of various treatments, including non-IgG small molecules and topical JAK inhibitors, to revolutionize psoriasis therapy while emphasizing the importance of individualized drug selection based on specific indications.
$100 - $150
Hourly Rate
Emerging systemic drugs in the treatment of plaque psoriasis.
London, UK
2 hours ago
1 Received
- - Psoriasis is a widespread chronic skin condition affecting 2-3% of the US population, causing significant psychosocial impacts, but effective therapies targeting IL-17 and IL-23 have emerged in recent years.
- - The article reviews current clinical trials for systemic biologic treatments and oral small molecule drugs to manage plaque psoriasis.
- - Although many with mild psoriasis might benefit from topical treatments or phototherapy, adherence issues exist, and while patients seek effective oral options, JAK inhibitors may not fully meet their needs due to their limitations.
$100 - $150
Hourly Rate
Interleukin 23p19 inhibitors in chronic plaque psoriasis with focus on mirikizumab: A narrative review.
London, UK
2 hours ago
1 Received
- Psoriasis is a chronic skin condition driven by T-cell activity, with complex causes that researchers are actively exploring to improve treatment options.
- Recent advancements have led to biologic drugs targeting specific immune pathways, including new IL-23p19 inhibitors that offer a safer approach to managing psoriasis.
- This review will focus on how IL-23 and Th17 cell signaling contribute to psoriasis and will summarize the clinical outcomes of using the IL-23p19 inhibitor mirikizumab in treating chronic plaque psoriasis.
$100 - $150
Hourly Rate
Clinical Trials of IL-12/IL-23 Inhibitors in Inflammatory Bowel Disease.
London, UK
2 hours ago
1 Received
- Inflammatory bowel diseases (IBDs), such as ulcerative colitis and Crohn's disease, are chronic conditions caused by an abnormal immune response influenced by various factors, including genetics and environment.
- The IL-23 pathway has a significant role in IBD by promoting an inflammatory response, particularly through Th17 cells.
- Treatments targeting IL-23, like the monoclonal antibody Ustekinumab and developing drugs like mirikizumab and risankizumab, show promise in managing moderate-to-severe IBD based on recent clinical trial data.
$100 - $150
Hourly Rate
Central Reading of Ulcerative Colitis Clinical Trial Videos Using Neural Networks.
London, UK
2 hours ago
1 Received
- Endoscopic disease activity scoring for ulcerative colitis (UC) is essential but rarely performed, leading to calls for automation through machine learning to improve clinical practice and research.
- Researchers collected 795 endoscopy videos from a trial involving 249 patients to train a recurrent neural network (RNN) that could predict endoscopic Mayo scores (eMS) and Ulcerative Colitis Endoscopic Index of Severity (UCEIS) from these videos.
- The RNN model showed excellent agreement with human expert scores, achieving a quadratic weighted kappa (QWK) of 0.844 for eMS and 0.855 for UCEIS, indicating its potential for effectively assessing UC severity in clinical settings.
$100 - $150
Hourly Rate
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
London, UK
2 hours ago
1 Received
- Psoriasis is a chronic immune-mediated disease that affects the skin and joints, significantly impacting quality of life, and while no cure exists, various treatments can manage the symptoms.
- This study aimed to conduct a network meta-analysis comparing the efficacy and safety of different treatment options (non-biological systemic agents, small molecules, and biologics) for moderate-to-severe psoriasis.
- The researchers reviewed numerous randomized controlled trials (RCTs) and focused on outcomes such as achieving clear skin, using established criteria like the Psoriasis Area and Severity Index (PASI).
$100 - $150
Hourly Rate
The IL23-IL17 Immune Axis in the Treatment of Ulcerative Colitis: Successes, Defeats, and Ongoing Challenges.
London, UK
2 hours ago
1 Received
- * Recent reviews of clinical trials highlight both potential benefits and limitations of targeting the IL23/IL17 axis as a treatment for UC, particularly focusing on the effectiveness of targeting IL23 p40 with Ustekinumab.
- * While Ustekinumab has shown promise in achieving clinical remission and improving quality of life, studies exploring other IL23 targets are ongoing, while no current research is examining direct IL17 pathway interventions in UC.
$100 - $150
Hourly Rate
Latest Advances for the Treatment of Chronic Plaque Psoriasis with Biologics and Oral Small Molecules.
London, UK
2 hours ago
1 Received
- * Advances in understanding psoriasis have led to new effective treatments, particularly biologicals targeting different immune pathways, including TNF-α, IL-12/23, IL-17, and IL-23 inhibitors.
- * The review focuses on the latest developments in biologicals and oral medications for chronic plaque psoriasis, highlighting promising new treatments in advanced clinical stages.
$100 - $150
Hourly Rate